cornerstone investors, page-4

Of the three possible cornerstone investors you name, the one that would surprise me the least is CSL.

CSL is Australian, first of all, and have first hand experience not only with POH, but with the Australian investment mileau.

Secondly, their collaboration with POH has delivered results that by all accounts exceeded expectations.

Thirdly, of all the potential applications of our TPM technology, the delivery of vaccines transdermally is potentially the most transformative and therefore crucial to CSL's future direction. The possibility of easy, clean and sterile with a simple alcohol wipe, and needle or puncture free delivery of vaccines that can be stored almost indefinitely without refrigeration opens up possibilities virtually beyond calculation.

CSL would gain hugely by taking a stake in a company that owns a technology so central to the future of vaccine delivery.

We'll see.